RESUMO
Chicken skeletal muscle satellite cells are located between the basement membrane and the sarcolemma of mature muscle fibers. Avian broilers have been genetically selected based on their high growth velocity and large muscle mass. The Wuding chicken is a famous local chicken in Yunnan Province that undergoes non-selection breeding and is slow growing. In this study, we aimed to explore differences in the proliferation and differentiation properties of satellite cells isolated from the two chicken breeds. Using immunofluorescence, hematoxylin-eosin staining and real-time polymerase chain reaction analysis, we analyzed the in vitro characteristics of proliferating and differentiating satellite cells isolated from the two chicken breeds. The growth curve of satellite cells was S-shaped, and cells from Wuding chickens entered the logarithmic phase and plateau phase 1 day later than those from Avian chicken. The results also showed that the two skeletal muscle satellite cell lines were positive for Pax7, MyoD and IGF-1. The expression of Pax7 followed a downward trend, whereas that of MyoD and IGF-1 first increased and subsequently decreased in cells isolated from the two chickens. These data indicated that the skeletal muscle satellite cells of Avian chicken grow and differentiate faster than did those of Wuding chickens. We suggest that the methods of breeding selection applied to these breeds regulate the characteristics of skeletal muscle satellite cells to influence muscle growth.
Assuntos
Galinhas/metabolismo , Células Satélites de Músculo Esquelético/citologia , Animais , Diferenciação Celular , Proliferação de Células , Forma Celular , Células Cultivadas , Imunofluorescência , Desenvolvimento Muscular , Reação em Cadeia da Polimerase em Tempo Real , Células Satélites de Músculo Esquelético/metabolismoRESUMO
Asthma is a chronic inflammatory disease of the airways with variable airflow obstruction and bronchial hyper-responsiveness. It is believed that Th2-derived cytokines orchestrate the asthmatic response and the maintenance of the balance of Th1/Th2 plays a crucial role in prevention of asthma. Moreover, 1,25(OH)2D3, the biologically activate form of vitamin D, was reported with an almost opposite role in prevention and treatment of asthma. Therefore, in this study, we elucidated the evaluations of in vivo anti-asthma effects when treated with different doses of vitamin D and validated the relationship between vitamin D and asthma. Our data demonstrated that intervention with the appropriate dose of 1,25(OH)2D3 in early life could improve pulmonary function and reduce eosinophil cell infiltration in the airways of rat asthma models. However, overdose might play a detrimental effect. Its mechanism may correlate with the effect of 1,25(OH)2D3 on interleukin (IL)-4, IL-12, IL-13, interferon-γ, and ovalbumin-specific immunoglobulin E secretion and the expression of p-JAK1/p-STAT6/SOCS5.
Assuntos
Asma/tratamento farmacológico , Vitamina D/administração & dosagem , Animais , Asma/imunologia , Suplementos Nutricionais , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Eosinófilos/efeitos dos fármacos , Eosinófilos/imunologia , Masculino , Distribuição Aleatória , Ratos , Ratos Wistar , Testes de Função Respiratória , Transdução de Sinais , Células Th1/efeitos dos fármacos , Células Th1/imunologia , Células Th2/imunologiaRESUMO
BACKGROUND: KRAS mutations have been associated with lung metastases at diagnosis of metastatic colorectal cancer (mCRC), but the impact of this mutation on subsequent development of lung metastasis is unknown. We investigated KRAS mutation as a predictor of lung metastasis development. METHODS: We retrospectively evaluated data from patients with mCRC whose tumour was tested for KRAS mutation from 2008 to 2010. The relationships of KRAS mutational status with time-to-lung metastasis (TTLM) and overall survival (OS) were analysed. RESULTS: Of the 494 patients identified, 202 (41%) had tumours with KRAS mutation. KRAS mutations were associated with a shorter TTLM (median 15.2 vs 22.4 months; hazard ratio=1.40; P=0.002) and a two-fold greater odds of developing lung metastases during the disease course in patients with liver-limited mCRC at diagnosis (72 vs 56%, P=0.007). Overall survival did not differ by KRAS status. CONCLUSIONS: Lung metastasis was more likely to develop during the disease course in patients whose tumour had a KRAS mutation than in those whose tumour did not have a KRAS mutation. This finding may have an impact on decision making for surgical resection of metastatic disease.